1 June 2012 -- Vernalis plc today announces three abstracts under its Hsp90 collaboration with Novartis
have been accepted for presentation at the 2012 American Society of Clinical Oncology
(ASCO) Annual Meeting, being held in Chicago from 1 to 5 June.
The abstracts can be viewed on the ASCO website www.abstract.asco.org/ConfCatView_114_S.html.
AUY922 is a novel intravenous Hsp90 inhibitor for the treatment of a range of solid tumours.
It was the first compound from a collaboration between Vernalis and Novartis to enter
clinical testing and has completed phase I trials and is currently in a number of phase II trials.
Novartis is conducting and funding future development and Vernalis will receive milestones
and royalties on successful development and commercialisation.
Ian Garland, Chief Executive Officer
+44 (0) 118 989 9360
David Mackney, Chief Financial Officer
+44 (0) 20 7404 5959
+44 (0) 20 7614 2900
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in taking promising product candidates along a commercially-focused path to market. The Group has one marketed product, frovatriptan for the acute treatment of migraine, and eight candidates in development, seven of which are designated priority programmes. Four of these priority development programmes are currently unpartnered and three are partnered. Pipeline programmes are derived from both our own research activities where we have significant expertise in fragment and structure based drug discovery, as well as from collaborations. Our technologies, capabilities and products are endorsed by collaborations with Endo, GSK, Lundbeck, Menarini, Novartis and Servier.